Stacy Enxing Seng, MBA, has been appointed president of Covidien's vascular therapies global business unit. She will report directly to Peter L. Wehrly, senior vice president and group president of respiratory & monitoring solutions and vascular therapies.
Enxing Seng, 47, will be responsible for managing a global organization of 4,000 employees with $1.4 billion in revenue. She joined Covidien in July 2010 through the ev3 acquisition, where she was a founding member and executive officer responsible for leading ev3’s peripheral vascular division from inception.
Prior to joining ev3, which was acquired by Covidien in July 2010 , she held various positions of increasing responsibility for Boston Scientific, Scimed Life Systems, Baxter Healthcare and American Hospital Supply. She received an MBA from Harvard University in Cambridge, Mass., and a bachelor’s degree from Michigan State University in East Lansing.